Therapeutic Response Statement (Sensitivity)

This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Rituximab in patients with Non-Hodgkin Lymphoma.

The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).

This statement is based on a regulatory approval from the Food and Drug Administration:

RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B- cell NHL as a single agent.

Citation

Genentech, Inc. Rituxan (rituximab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103705s5467lbl.pdf. Revised December 2021. Accessed October 30, 2024.